RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates & survival outcomes in patients with metastatic BRAFV600E ColorectalCancer treated with anti-BRAF/EGFR therapy. NMEDclinical

HEK293T cells were used for the assays, cultured in DMEM supplemented with 10% FBS . Cells were cultured in a humidified incubator maintained at 37 °C with 5% CO. Cells tested negative for mycoplasma based on the real-time PCR method at Eurofins GATC-Biotech . Identity of the HEK293T cells was confirmed by the Erasmus Molecular Diagnostics Department, using PowerPlex-16 STR genotyping .

PFS was defined as the time from anti-BRAF/EGFR therapy initiation to disease progression or death, whichever occurred first. OS was defined as the time from anti-BRAF/EGFR therapy initiation to death from any cause. PFS and OS were estimated using the Kaplan–Meier method and compared by the log-rank test. Cox proportional-hazard models were used to obtain HRs with 95% CIs. Formal statistical testing was only used in the validation cohort. No data imputation was performed.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy - Nature MedicineSingle-cell proteomic profiling of circulating CART cells in patients treated with CD19-CAR shows that CD4+Helios+ CAR Treg cells on day 7 after infusion are associated with progressive disease & less severe neurotoxicity in patients with LBCL. Thank you for highlighting our work! We found that this CAR Treg population is Helios+ FOXP3+, and quantification based on either marker led to nearly identical results.
Source: NatureMedicine - 🏆 451. / 53 Read more »

A combined stem-cell–gene therapy strategy for ALS - Nature MedicineNews & Views: Scientists developed a combined stem-cell and genetherapy strategy for ALS. Hideyuki Okano discusses the first clinical results, which will inform further clinical trials of this neurodegenerative disease. MIT mcgovernmit KeioGlobal
Source: NatureMedicine - 🏆 451. / 53 Read more »

New Cancer Drug Beats Chemotherapy in StudyAmgen’s new cancer drug, targeting the common mutation KRAS, beat chemotherapy in a study, but the results leave room for rivals with drugs in the works
Source: WSJhealth - 🏆 413. / 53 Read more »

Wastewater surveillance of pathogens can inform public health responses - Nature MedicineWastewater monitoring has been used to identify SARS-CoV-2 outbreaks and track new variants. This sentinel system should be expanded to monitor other pathogens and boost public health preparedness. svscarpino RockefellerFdn Incredible team of co-authors: MathematicaNow JasonVogel1 MarleneKWolfe lauren_stadler AnisabelBento Tedsmithphd ZacharySusswein svscarpino & more
Source: NatureMedicine - 🏆 451. / 53 Read more »

How to correct the market for children’s cancer drugs - Nature MedicineHow to correct the market for children’s cancer drugs The development of pediatric cancer drugs is vastly underfunded compared with that for adults, but legislation can correct market failures. ChildhoodCancerAwarenessMonth CancerTherapy
Source: NatureMedicine - 🏆 451. / 53 Read more »